SCHEMBL6435599

SCHEMBL6435599

N=C(N)N(Cl)c1cncc2cc(S(=O)(=O)Nc3cccc(C(=O)O)c3)ccc12

nearest known ligand 0.52

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
PLG P00747 1/20 0.52
PLAU P00749 1/20 0.52
MEN1 O00255 4/20 0.48
KMT2A Q03164 4/20 0.48
POLB P06746 3/20 0.48
MAPT P10636 1/20 0.46
PFKFB3 Q16875 1/20 0.46
AKR1C3 P42330 1/20 0.45
HSD17B10 Q99714 2/20 0.45
ATIC P31939 2/20 0.45
CYP2C9 P11712 1/20 0.45
CYP2C19 P33261 1/20 0.45
WDR5 P61964 1/20 0.43
ALDH1A1 P00352 1/20 0.42
THRB P10828 1/20 0.41
CASP3 P42574 1/20 0.41
SENP8 Q96LD8 1/20 0.41
SENP7 Q9BQF6 1/20 0.41
SENP6 Q9GZR1 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Trifluoroacetic Acid SCHEMBL6436929 0.95 PLG (0.48) PLGPLAUMEN1KMT2APOLB
SCHEMBL7049180 0.87 F2 (0.42) PLGPLAUMAPTATICALDH1A1
SCHEMBL6436458 0.82 PLG (0.52) PLGPLAUMEN1KMT2APOLB
Hydrochloric Acid SCHEMBL6433178 0.81 PLG (0.51) PLGPLAUMEN1KMT2APOLB
Hydrochloric Acid SCHEMBL7370328 0.81 ALDH1A1 (0.44) MEN1KMT2APOLBCYP2C9WDR5
SCHEMBL7379442 0.80 PLG (0.54) PLGPLAUMEN1KMT2APOLB
SCHEMBL7065586 0.79 PLAU (0.45) PLAU
SCHEMBL7373625 0.78 MEN1 (0.31) PLAUMEN1KMT2A
SCHEMBL6434174 0.77 PLAU (0.50) PLGPLAUTHRB
SCHEMBL7380233 0.76 PLAU (0.39) PLGPLAUMEN1KMT2AMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050026836-A1 Composition for the treatment of damaged tissue DACK KEVIN NEIL (GB) 2005-02-03 US disclosed
US-20030199440-A1 Composition for the treatment of damaged tissue PFIZER INC. 2003-10-23 US disclosed
EP-1077945-B1 ISOQUINOLINES AS UROKINASE INHIBITORS PFIZER (US) 2003-01-08 EP disclosed
EP-1077945-A1 ISOQUINOLINES AS UROKINASE INHIBITORS PFIZER INC. (US) 2001-02-28 EP disclosed
US-6093731-A Isoquinolines PFIZER INC. 2000-07-25 US disclosed
WO-2000005214-A2 ISOQUINOLINES AS UROKINASE INHIBITORS PFIZER INC. (US) 2000-02-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030199440-A1 Composition for the treatment of damaged tissue MMP1, SERPINE1, COL14A1 PLG 33/4885PLAU 119/4885MEN1 4591/4885
US-20050026836-A1 Composition for the treatment of damaged tissue MMP1, SERPINE1, COL14A1 PLG 33/4885PLAU 119/4885MEN1 4591/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.